Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC.
- DOI
- 10.1016/j.tjpad.2026.100598
- Published
- 2026 Aug
- Container
- The journal of prevention of Alzheimer's disease
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.tjpad.2026.100598,
title = {Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC.},
author = {Frederiksen KS and Boada M and Frölich L and Kramberger M and Scarmeas N and Vijverberg E and Visser PJ and Waldemar G and Westman E and Zetterberg H and Engelborghs S and Jessen F},
year = {2026},
journal = {The journal of prevention of Alzheimer's disease},
doi = {10.1016/j.tjpad.2026.100598},
url = {https://doi.org/10.1016/j.tjpad.2026.100598}
}RIS
TY - JOUR TI - Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC. AU - Frederiksen KS AU - Boada M AU - Frölich L AU - Kramberger M AU - Scarmeas N AU - Vijverberg E AU - Visser PJ AU - Waldemar G AU - Westman E AU - Zetterberg H AU - Engelborghs S AU - Jessen F PY - 2026 JO - The journal of prevention of Alzheimer's disease DO - 10.1016/j.tjpad.2026.100598 UR - https://doi.org/10.1016/j.tjpad.2026.100598 ER -
APA
KS, F., M, B., L, F., M, K., N, S., E, V., PJ, V., G, W., E, W., H, Z., S, E., & F, J. (2026). Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC.. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2026.100598
Source records
- pubmed · retrieved 2026-09-25T18:19:59.652Z